The Effect of Standardizing Procedures for SC Injections of LMWH on Patients With CVD

NCT ID: NCT06776159

Last Updated: 2025-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-24

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Improper subcutaneous administration of LMWH may cause complications at the injection site. Standardized protocol for subcutaneous LMWH injections in patient with cardiovascular diseases is warranted to ensure consistent best practices in clinical settings.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study examines the effect of standardized protocol in reducing complications for patients with cardiovascular disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CVD - Cardiovascular Disease Bruise Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double-blinded, two-armed, clustered randomized controlled trial.
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
The administrative staff, who will be responsible for data collection, will be masked for the group allocation during the whole process. The patients will be masked for the intervention purpose.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Control

The control group participants will receive the usual practice of subcutaneous LMWH injection administered by nurses.

Group Type ACTIVE_COMPARATOR

Active Control

Intervention Type OTHER

Patients in the control group will receive the usual practice of subcutaneous LMWH injection administered by nurses.

Standardized injection protocol

The intervention group participants will receive standardized LMWH injection administered by nurses.

Group Type EXPERIMENTAL

Standardized injection protocol

Intervention Type OTHER

Nurses administer LMWH according to the standardized evidence-based protocol.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active Control

Patients in the control group will receive the usual practice of subcutaneous LMWH injection administered by nurses.

Intervention Type OTHER

Standardized injection protocol

Nurses administer LMWH according to the standardized evidence-based protocol.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who are in cardiac care units suffering from cardiovascular diseases prescribed with LMWH injections two times per day
* Chinese

Exclusion Criteria

* cognitively impaired
* unconscious
* refuse to participate
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Hong Kong Polytechnic University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

CHEUNG Pui Yu Frankie

Assistant Professor of Practice

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Arkers Wong

Role: PRINCIPAL_INVESTIGATOR

The Hong Kong Polytechnic University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Authority, Hong Kong

Hong Kong, , Hong Kong

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Frankie CHEUNG

Role: CONTACT

852 2766 7991

Arkers Wong

Role: CONTACT

852 3400 3805

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHEUNGPuiYu

Identifier Type: OTHER

Identifier Source: secondary_id

20250301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.